T he biological defense system in mammals comprises innate and acquired immunities. Granulocytes, the majority of which are neutrophils in the peripheral blood, are involved in innate immune responses by monitoring infections and scavenging toxic substances. When infections or tissue injuries occur, neutrophils immediately transmigrate from the bloodstream into inflammatory sites (1) (2) (3) . Some CXC chemokines such as IL-8, complement-related factors such as the activated C component 3 and C component 5 (C5a), 5 and other small molecules such as leukotriene B 4 and plateletactivating factor induce neutrophil infiltration into inflammatory sites (1) (2) (3) (4) . N-terminal formylated peptides originating from bacterial proteins reportedly activate neutrophils by binding to receptor molecules for formylated peptides expressed in neutrophils (3, 5, 6) . Mammalian proteins encoded by nuclear DNA lack a formyl group at the N terminus, whereas those encoded by mitochondrial DNA are N-terminally formylated, suggesting that mitochondrial proteins and their Nterminal peptides could also be neutrophil-activating substances. In fact, it is reported that the contents of disrupted mitochondria induced neutrophil migration, suggesting the presence of molecules in mitochondria that cause the migration and activation of neutrophils (7) . Additionally, chemically synthesized N-terminal formylated peptides derived from mitochondrial NADH dehydrogenase subunit I were shown to induce chemotactic migration of neutrophils (8) . However, direct lines of evidence of the presence of such mitochondrial peptides in mammalian tissues have not been demonstrated to date. We conceived that factors inducing rapid neutrophil migration from the bloodstream to inflammatory sites after the occurrence of tissue injury are present even in healthy tissues. Heart tissue should be considered as one of the appropriate tissues for purifying these neutrophil-activating factors because immediate and dramatic infiltration of neutrophils after ischemia-reperfusion injury in the heart reportedly causes severe tissue damage (9 -11) . Moreover, the underlying mechanism responsible for the induction of rapid *Institute of Applied Biochemistry, University of Tsukuba, Tsukuba, Ibaraki, Japan; † Laboratory of Peptide Biosignal Engineering, Mitsubishi Kagaku Institute of Life Sciences, Machida, Tokyo, Japan; ‡ Laboratory of Life Science and Biomolecular Engineering, JT Inc., Yokohama, Kanagawa, Japan; § 21st Century COE Program, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan; neutrophilic invasion in ischemia injury has not yet been fully clarified. Therefore, we attempted to purify such neutrophil-activating factors from the heart, and have recently discovered mitocryptide-1 (MCT-1), a neutrophil-activating peptide derived from mitochondrial cytochrome c oxidase subunit VIII (12) . In our previous study, the presence of many unidentified neutrophil-activating peptides in the heart tissue has also been suggested. Here, we developed purification and analytical procedures and succeeded in identifying another class of a neutrophil-activating peptide from the porcine heart whose N-terminal was formylated.
Materials and Methods
Peptides that activate neutrophils were purified from healthy porcine hearts as described previously (12) with several modifications for improvement of purification (outlined in Fig. 1 ). The activity of the purified fractions was monitored by assessing the induction of ␤-hexosaminidase (␤-HA) release from HL-60 cells differentiated into neutrophilic/granulocytic cells. These cells share a number of common features with neutrophils (13) (14) (15) (16) . ␤-HA can be easily assessed quantitatively and the enzyme is known to be released from HL-60 cells differentiated into neutrophilic/granulocytic cells as well as neutrophils by the stimulation of well-known neutrophil-activating factors such as C5a and formyl-Met-Leu-Phe (fMLF) (12) (13) (14) (15) .
Extraction and purification
Porcine hearts (ϳ13.2 kg) were harvested immediately after sacrifice and washed with ice-cold physiologic saline. The hearts were sliced thinly and boiled in 100 liters of ion-exchanged water for 10 min to prevent proteolytic fragmentation (17) . The boiled tissue and supernatant were cooled to room temperature and then homogenized together in 1 M acetic acid (AcOH) containing 20 mM HCl for 10 min in a whirling blender. After the addition of 25 liters of 1 M AcOH-20 mM HCl to the homogenate, peptides were extracted by stirring at 4°C for 18 h. The homogenate was centrifuged at 20,000 ϫ g for 10 min at 4°C, and the supernatant was concentrated to 15 liters in vacuo. Then, 22.5 liters of ice-cold acetone was added to the concentrated supernatant (to yield a final acetone concentration of 60%), and the mixture was stirred at 4°C for 20 h. The extracted solution was concentrated in vacuo after centrifugation at 20,000 ϫ g for 10 min at 4°C. The concentrated supernatant was washed twice with diethyl ether as a degreaser, and the extracted solution was concentrated to 1 liter in vacuo. The concentrated extracted solution was centrifuged further (20,000 ϫ g, 30 min, 4°C) to remove insoluble materials, and the supernatant was concentrated and lyophilized to give a crude extracted powder.
One-sixth (by weight) of the lyophilized crude extract was dissolved in 300 ml of 1 M AcOH and loaded on a SP-Sephadex C-25 column (7 ϫ 37.5 cm; GE Healthcare Bio-Science) for cation-exchange chromatography. The eluent was separated into three fractions subsequently: fraction A was eluted with 1 M AcOH, fraction P was eluted with 2 M pyridine, and fraction PA was eluted with 2 M pyridine-AcOH (pH 5.0). The respective fractions were concentrated, lyophilized, and stored at Ϫ80°C until subsequent purification. This process was repeated until all of the crude extract had been fractionated.
Next, one-sixth of the lyophilized powder of the PA fraction was dissolved in 80 ml of 0.1 M AcOH and subjected to gel filtration chromatography on a Sephadex G-25 column (4 ϫ 146 cm; GE Healthcare BioScience) with 0.1 M AcOH. We collected 10-ml aliquots of eluate and determined the effect of each fraction on ␤-HA secretion from HL-60 cells differentiated into neutrophilic/granulocytic cells as follows. The fractions were combined according to their activity, as indicated in Fig. 2A (PAG1, PAG2, and PAG3). This purification step was repeated until the entire PA fraction had been purified, lyophilized, and stored at Ϫ80°C.
The active PAG1 fraction was purified by reverse-phase (RP)-HPLC on a preparative octadecylsilane (ODS) column (20 ϫ 250 mm; YMC) using a linear gradient of acetonitrile at a flow rate of 5 ml/min in the presence of 0.1% trifluoroacetic acid (TFA) and with absorbance monitoring at 230 nm (see Fig. 2B ). The fractions with considerable activity that eluted at acetonitrile concentrations of 27-31% on a preparative ODS column were combined as the PAG1-I fraction (see Fig. 2B ) and concentrated by evaporators. Then, this fraction was HPLC-fractionated on a cation-exchange column (TSK-CM2SW, 4.6 ϫ 250 mm; Tosoh) using a linear gradient of ammonium formate in the presence of 10% acetonitrile (adjusted to pH 6.6) at a flow rate of 1 ml/min and by monitoring the absorbance at 280 nm (see Fig. 2C ). We collected 1-ml aliquots of eluate, and the fractions with activity, which eluted at ammonium formate concentrations of 234 -241 mM, were combined as the PAG1-I-c fraction. This fraction was purified further by micro-RP-HPLC using an analytical C4 column (Develosil C4, 1.0 ϫ 150 mm; Nomura Chemical), a linear gradient of acetonitrile in the presence of 0.1% TFA, and a flow rate of 50 l/min, with monitoring at 214 nm (see Fig. 3A ). Each fraction of 50 l of eluate was collected and lyophilized, and the fraction having the highest activity (PAG1-I-c2, see Fig.  3A ), which eluted at an acetonitrile concentration of 26%, was then purified by micro-RP-HPLC on an analytical ODS column (Develosil ODS-HG5, 1.0 ϫ 250 mm; Nomura Chemical) using a linear gradient of acetonitrile in the presence of 0.1% TFA at a flow rate of 50 l/min (see Fig. 3B ); the fraction with peak activity eluted at an acetonitrile concentration of ϳ26%. This fraction (PAG1-I-c2 peak) was purified again by micro RP-HPLC using the same conditions (see Fig. 3C ). The fraction with peak activity (PAG1-I-c2 peak-peak) was used in the structural analyses.
Structural analyses and peptide synthesis
The amino acid sequence of the peptide was analyzed according to the Edman method using an automated sequencer (PPSQ-10; Shimadzu) (18) . The Arg-C (Roche Diagnostics) proteolytic products of the purified peptide were purified by micro-RP-HPLC on an analytical ODS column (Develosil ODS-HG5, 1.0 ϫ 250 mm; Nomura Chemical) using the same condition described above, and their amino acid sequences were analyzed by the automated Edman degradation method. For additional structural information, fast atom bombardment (FAB) mass spectrometry (MS) (FAB-MS; JMX-HX/HX10A; JEOL) was used to obtain MS/MS spectra (19) . The peptides used in the present study were chemically synthesized by the solid-phase strategy using the t-butyloxycarbonyl method described previously (20 -22) . All of the peptides were proven to have a purity of Ͼ95% by analytical RP-HPLC. The identity of the peptides was also confirmed by amino acid analysis after acid hydrolysis with 6 N HCl and MALDI-TOF-MS.
Preparation of cells
Human acute leukemia-derived HL-60 cells were obtained from RIKEN Cell Bank. Cells were cultured in RPMI 1640 medium (Invitrogen) containing 10% FBS (HyClone) in a humidified atmosphere of 5% CO 2 at 37°C. To differentiate HL-60 cells into neutrophilic/granulocytic cells, the cells were treated with 500 M dibutyryl cyclic AMP for 72 h, as described elsewhere (12, 13) , since it has been reported that dibutyryl cyclic AMP differentiates HL-60 cells efficiently with respect to the expression of formyl peptide receptors and lysosomal enzyme release stimulated by known neutrophil-activating factors (12, 13) .
Human neutrophils were obtained from healthy volunteers as described (12, 23); 20 ml of peripheral blood containing 500 U of heparin sodium was divided into four aliquots, each of which was layered onto 5 ml of Polymorphoprep (Axis-Shield) and centrifuged at 500 ϫ g for 30 min at 4°C. After spinning, neutrophils were collected and transferred to a fresh 15-ml conical tube. The purity of the cell preparation was confirmed to be Ͼ98% as determined using Randolph's stain. suspended in ice-cold HBHS, and kept on ice until stimulation with peptides.
Assay of ␤-HA release
To evaluate the activities of purified fractions or to examine the effects of synthetic peptides, ␤-HA release from HL-60 cells differentiated into neutrophilic/granulocytic cells and human neutrophils was first assessed (12) . Namely, the cells (neutrophils or HL-60 cells differentiated into neutrophilic/granulocytic cells) were washed three times with ice-cold HBHS and resuspended in HBHS at a density of 5.5 ϫ 10 6 cells/ml. Then, 90 l of the cell suspension was transferred to a tube (5 ϫ 10 5 cells/tube) and placed on ice; cytochalasin B and DNase I were added to give a final concentration of 5 g/ml of each reagent. Tubes were preincubated at 37°C for 10 min, and a purified fraction or synthetic peptide solution (10 l) was added; tubes were further incubated at 37°C for 10 min to stimulate the cells. To estimate the total enzyme content, 10 l of 0.5% Triton X-100 (final concentration, 0.05%) was added to the cell suspension (90 l); 10 l of distilled water was added to the cells for a negative control. After the 10-min incubation at 37°C, 200 l of ice-cold reaction quenching buffer (25 mM Tris, 123 mM NaCl, and 2.7 mM KCl (pH 7.4)) was added to each reaction to stop the stimulation of the cells. Thereafter, tubes were spun at 4°C and 5000 rpm for 60 s, and the activities of ␤-HA in the supernatant were measured as described below.
␤-HA activity in the cell-free supernatant was measured as described previously (12, 24) . In brief, 90 l of the supernatant described earlier was transferred to wells of a 96-well plate (Nunc), and then 60 l of a substrate solution for ␤-HA (10 mM p-nitrophenyl N-acetyl-␤-D-glucosaminide (Sigma-Aldrich), 40 mM citrate, and 70 mM NaHPO 4 (pH 4.5)) was added to initiate an enzymatic reaction. After incubation of the plate at 37°C for 1 h, 100 l of 0.4 M glycine (pH 10.7) was added to stop the reaction, and the absorbance difference of each well at 415 nm for the resulting p-nitrophenol and at 490 nm for the reference was measured. The ␤-HA enzyme activity secreted in the cell supernatant was expressed either as a percentage of the total enzyme activity, which was the enzyme activity released after disruption of the cells with 0.05% Triton X-100 (i.e., secreted activity/ total activity ϫ 100%), or as a percentage of the activity secreted by induction with 10 M fMLF.
Assay of lactate dehydrogenase (LDH) activity leaked from cells
To examine cell damage induced by the purified fractions or synthetic peptides, the LDH activity leaked from the cells was measured, as described previously (12, 24) . Briefly, 400 l of a substrate-buffer solution (125 mM 2-amino-2-methyl-1-propanol, 125 mM lithium lactate, and 6.25 mM NAD (pH 9.5)) was added to 100 l of the cell supernatant obtained in the experiment involving ␤-HA release as induced by the peptides described above, and the mixture was incubated for 1 h at 37°C. The reaction was quenched in ice, and the change in absorbance at 340 nm was measured. The LDH activity leaked from the cells was calculated as the percentage of the total enzyme activity in the cells, which was the activity of LDH released after disruption of the cells with 0.05% Triton X-100. The purified fraction with ␤-HA-releasing activity shown in Fig. 3C or all synthetic peptides used at concentrations up to 300 M did not induce significant leakage of LDH from HL-60 cells differentiated into neutrophilic/ granulocytic cells (purified fraction and all synthetic peptides) or human neutrophils (synthetic peptides).
Chemotaxis assay
The chemotactic activity of peptides was measured using Chemotaxicell chambers (pore size of filter membrane, 3 m; Kurabo), as described previously (12) . Cells were washed three times with ice-cold HBHS and were then resuspended in ice-cold HBHS to a density of 4 ϫ 10 6 cells/ml. After preheating to 37°C, 500 l of the cell suspension was transferred to each Chemotaxicell chamber (2 ϫ 10 6 cells/chamber), which was then placed in each well of a 24-well microplate, in which each well contained 1 ml of preheated (37°C) HBHS containing peptide(s), and incubated for 1 h at 37°C. Then, Chemotaxicell chambers were removed from the plate after rinsing the lower side of the filter membrane by pipetting to recover the cells loosely adhered to the lower chamber side of the filter membrane, and then the cells in the lower wells were counted. The viability of the migrated cells was confirmed to be Ͼ95% by trypan blue staining. Migration activity was expressed as a chemotaxis index, which was the number of cells that migrated after stimulation divided by the number of cells that migrated by vehicle.
Measurement of intracellular free Ca 2ϩ concentration ([Ca 2ϩ ] i )
The increases in [Ca 2ϩ ] i as stimulated by the peptides were assessed as described (25) (26) (27) . In brief, the HL-60 cells differentiated into neutrophilic/ granulocytic cells were washed twice with a HEPES-Na solution (5 mM HEPES, 140 mM NaCl, 4 mM KCl, 1 mM NaH 2 PO 4 , 1 mM MgCl 2 , 1.25 mM CaCl 2 , 11 mM glucose, and 0.2% BSA at pH 7.4). The Ca 2ϩ -sensitive fluorescence reagent fura-2/AM (Molecular Probes) was then added to the cell suspension (4 ml to a final concentration of 4 M). The reaction mixture was shielded from light and shaken gently at room temperature for 60 min to load fura-2 into the differentiated HL-60 cells. The cells were subsequently washed twice with the HEPES-Na solution and a cell suspension was diluted to a final density of 1.0 ϫ 10 6 cells/ml. The cell suspension (1 ml) was placed into a cuvette with stirring and stimulated with peptides with stirring at 30°C. Using excitation wavelengths of 340 and 380 nm, the ratio of fluorescence intensity at 500 nm was measured with a fluorometer (CAF-100; Japan Spectroscopic). [Ca 2ϩ ] i was then calculated as described previously (26 -28) .
Treatment of cells with pertussis toxin (PTX)
To examine the inhibitory effects of PTX, cells were preincubated in 50 ng/ml PTX (List Biological Laboratories) at 37°C for 16 h, and ␤-HA release, chemotaxis, and the increase in [Ca 2ϩ ] i were measured in the PTXtreated or control cells as described previously (12) .
Binding assay
To assess the binding activities of the peptides to the HL-60 cells differentiated into neutrophilic/granulocytic cells, the cells were washed three times with ice-cold PBS and resuspended in PBS containing 0.1% BSA at a density of 1.1 ϫ 10 7 cells/ml on ice. A total of 90 l of the cell suspension was added to a tube (1 ϫ 10 6 cells/tube) containing 10 l of a solution of [ 3 H]fMLF (final concentration, 20 nM; PerkinElmer) with or without competitive peptides, and incubated at 4°C for 4 h. Then, 900 l of ice-cold PBS was added to each tube, and the content of a tube was quickly filtered using the GF/C glass filter (GE Healthcare Bio-Science). The filter was washed with 3 ml of ice-cold PBS four times, dried using a white lamp, and its radioactivity was measured using a scintillation reagent. Specific binding was estimated by subtracting the value obtained in the presence of 100 M nonlabeled fMLF.
Statistical analysis
For the comparison of experimental values, Student's t test for unpaired data was used to determine statistical significance as described previously (20, 21) . Values of p Ͻ 0.05 were considered to be significant.
Results
CXC chemokines (e.g., IL-8) have been implicated in the induction of neutrophil infiltration into damaged tissues of the heart and lung after reperfusion injuries (1-4, 29) . However, the mechanisms underlying the actions of neutrophils at injury sites are not well understood. For example, neutrophil migration after reperfusion injury in tissues such as the heart and lung appears to be very rapid, suggesting that substances inducing such migration may exist even in healthy tissues. The presence of many kinds of neutrophil-activating peptides in various healthy organ extracts including those from the heart has been observed in preliminary experiments (H. Mukai and E. Munekata, unpublished observation). We therefore attempted to identify peptidergic neutrophil-activating factors by purifying them from the porcine heart because most of these factors become biologically mature after proteolytic cleavage, and it is very difficult to apply recently developed molecular biology techniques. The activity of candidate factors was assessed by measuring ␤-HA release from HL-60 cells differentiated into neutrophilic/granulocytic cells, since these cells have a number of similar features with neutrophils, including the stimulation of ␤-HA release by well-known neutrophil-activating factors (12) (13) (14) (15) (16) . ␤-HA can also be easily assayed with high throughput (24) .
Extraction and purification
Here, we successfully extracted and purified a neutrophil-activating peptide from porcine heart (Figs. 1-3) . First, we extracted peptides contained in porcine hearts with 1 M AcOH-20 mM HCl after inactivating endogenous proteases by boiling. It has been reported that fragmentation of proteins during the extraction and purification steps can be prevented by the immediate boiling of tissues to inactivate various proteases (17) . Many bioactive peptides including atrial natriuretic polypeptide and ghrelin have been actually purified using this method (30, 31) . Most peptides, particularly linear peptides, are stable in boiling treatment in distilled water; nevertheless, it is difficult to completely rule out the possibility that the isolated peptides are produced during the extraction steps.
Following the removal of various proteins by acetone precipitation, we separated a crude extract into three fractions by cationexchange chromatography using SP-Sephadex C-25 (Fig. 1) . Because the PA fraction eluted with 2 M pyridine-AcOH (pH 5.0) markedly stimulated ␤-HA release from differentiated HL-60 cells, we further purified this fraction by gel filtration chromatography using Sephadex G-25. As shown in Fig. 2A , the active fractions were separated as three major activity peaks, and the fractions FIGURE 2. Fractionation of the peptide by gel filtration using a Sephadex G25 column (A), preparative RP-HPLC using an ODS column (B), and ion-exchange HPLC using a cation-exchange column (C). The ability of each fraction to cause ␤-HA release, indicated by an open circle (A) or a filled bar (B and C), was expressed either as a percentage of the total enzyme activity, which was the enzyme activity released after disruption of the cells with 0.05% Triton X-100 (%/total) in A, or as a percentage of the activity secreted by induction with 10 M fMLF (%/control) in B and C.
showing the activity eluted at 650-1010 ml with the fraction having the highest potency eluted at 800 -810 ml (activity, 59.4% of total enzyme content) were combined as the PAG1 fraction. We concentrated this fraction and then purified it by preparative RP-HPLC using an ODS column (Fig. 2B) . The potent five fractions for inducing ␤-HA release eluted at acetonitrile concentrations of 27-31% (activities, 52.9%, 66.2%, 66.6%, 64.7%, and 37.6% of the positive control, which was stimulated with 10 M fMLF) as obtained by purification using preparative RP-HPLC, were combined as the PAG1-I fraction (Fig. 2B) . The following purification by cation-exchange HPLC gave three major fractions with ␤-HAreleasing activity (i.e., PAG1-I-a, PAG1-I-b, and PAG1-I-c; Fig.  2C ). We further purified the combined PAG1-I-c fraction (activities of two original fractions, 106.1% and 113% of the positive control), which had the highest activity among the three combined fractions, by micro-RP-HPLC using a C4 column. This process yielded three active fractions: PAG1-I-c1, PAG1-I-c2, and PAG1-I-c3 (Fig. 3A) . The most active fraction (PAG1-I-c2; activity, 105.0% of the positive control) was then purified twice by micro-RP-HPLC using an analytical ODS column (Fig. 3, B and C) , ultimately yielding the active PAG1-I-c2 peak-peak fraction. The substance in the PAG1-I-c2 peak-peak fraction (activity, 89.7% of the positive control) underwent structural analysis.
Identification
We first attempted to analyze the amino acid sequence of the substance in the active PAG1-I-c2 peak-peak fraction by the automated Edman degradation method (18) , but no information could be obtained. This result suggests the possibility of N-terminal modification of the peptide. We therefore subjected the substance to MS/MS analysis using FAB-MS (19) . The ions sequentially cleaved from the N terminus, and we were able to obtain the following peptide information: N terminus, (260)-(227)-Arg-Lys/ Gln-Ser-His-Pro-Leu-(numbers in parentheses indicate the approximate molecular masses of the parts). This result indicates the presence of a peptidergic substance in the fraction, so we treated the PAG1-I-c2 peak-peak fraction with proteolytic enzyme Arg-C for 16 h at 37°C. This enzyme cleaves peptide bonds of the carboxyl side of basic amino acid residues and is somewhat selective for Arg residues over Lys residues. The cleaved peptides were purified by micro-RP-HPLC using an analytical ODS column (Fig.  4) . We collected four major peaks and analyzed the amino acid sequences of the corresponding peptides by the Edman method. We were able to obtain the amino acid sequences of peaks A, C, and D but not that of peak B (Fig. 4) . The amino acid sequence from peak A was one part of that from peak C, demonstrating that the partial amino acid sequence of the peptide in the active PAG1-I-c2 peak-peak fraction was Lys-Ser-His-Pro-Leu-Met-Lys-Ile-IleAsn. Additionally, it was also shown that the peptide in the active fraction had the X-Asn-Ile-Arg sequence (X, unidentified amino acid residue), which was obtained from the analysis of peak D.
We performed FASTA search of the former sequence, Lys-SerHis-Pro-Leu-Met-Lys-Ile-Ile-Asn, using the protein databank Swiss-Prot and found that this sequence was identical to that of porcine mitochondrial cytochrome b 6 -15 . Moreover, our structural analyses revealed that the peptide in the PAG1-I-c2 peak-peak fraction was the N-terminal pentadecapeptide of porcine cytochrome b (pfCytB) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] with formylation of its N terminus; our assignment of the structure was based on the following: 1) pfCytB [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] contained not only the Lys-Ser-His-Pro-Leu-Met-LysIle-Ile-Asn sequence obtained from peaks A and C, but also the X-Asn-Ile-Arg sequence from peak D (Fig. 4) ; 2) any sequence information of the full-length peptide could not be obtained by Edman degradation, suggesting N-terminal modification; and 3) information from the MS/MS analysis was consistent with the amino acid sequence of pfCytB [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Thus, the primary structure of the full-length target peptide indicated by the structural analyses was formyl-Met-Thr-Asn-Ile-Arg-Lys-Ser-His-Pro-Leu-MetLys-Ile-Ile-Asn.
We named this N-terminal formylated pentadecapeptide "mitocryptide-2" (MCT-2) because it is a functional cryptic peptide hidden in mitochondrial cytochrome b, and because we purified and identified it as the second neutrophil-activating peptide derived from mitochondrial protein sequences (12) . We should, however, state that the calculated molecular weight of the peptide is 1824.23, whereas the measured value was 1806.47, suggesting further peptide modifications. Unfortunately, we could not determine the modification(s) of MCT-2 other than N-terminal formylation because of limited amounts of the purified fraction.
Biological evaluation
Next, we chemically synthesized MCT-2 without any modifications other than N-terminal formylation to confirm whether the MCT-2 sequence (Fig. 5A) is a biologically functional peptide. Moreover, we deduced the human homolog of MCT-2 (i.e., hMCT-2, the primary sequence of which is shown in Fig. 5A ) from the primary structure of its parent protein human cytochrome b, and we investigated its ability to induce ␤-HA release. As shown in Fig. 5B , chemically synthesized MCT-2 and hMCT-2 induced not only ␤-HA release but also chemotaxis of HL-60 cells differentiated into neutrophilic/granulocytic cells in concentration-dependent manners (EC 50 s of MCT-2, 3.8 ϫ 10
Ϫ8 M for ␤-HA release and 6.2 ϫ 10 Ϫ9 M for chemotaxis; EC 50 s of hMCT-2, 5.63 ϫ 10 Ϫ8 M for ␤-HA release and 7.9 ϫ 10 Ϫ9 M for chemotaxis), just as the bacterial model peptide fMLF did. Moreover, MCT-2 and hMCT-2 showed no effects on nondifferentiated HL-60 cells (data not shown). Additionally, even at concentrations as high as 300 M, MCT-2 and hMCT-2 caused no marked LDH leakage from differentiated or nondifferentiated HL-60 cells. These findings indicate that MCT-2 and hMCT-2 are the biologically active peptides even without any unidentified modifications other than N-terminal formylation, and it is favorable to propose that MCT-2 with unidentified modification(s) is the molecule responsible for the activity of the PAG1-I-c2 peak-peak fraction.
Mechanisms of cell activation
What molecules act as receptors for MCT-2? N-terminal formylated peptides and proteins such as fMLF are known to induce FIGURE 4. Separation of Arg-C proteolytic digests by micro-RP-HPLC. The PAG1-I-c2 peak-peak fraction was treated with the proteolytic enzyme Arg-C and separated by micro-RP-HPLC under a gradient of acetonitrile in the presence of 0.1% TFA. The digested fractions were eluted at a flow rate of 50 l/min, and absorbance at 214 nm was monitored to identify digested peptides. The amino acid sequences determined by Edman degradation analysis were indicated for each major peak.
chemotaxis of neutrophils (1-3) . Additionally, three G proteincoupled receptors of the formyl peptide receptor (FPR) family, namely, FPR, FPR-like 1 (FPRL1), and FPR-like 2 (FPRL2) (3), have been reported to function as receptors for formylated peptides, demonstrating that the formyl group at the N terminus of these peptides is important for the binding and activation of these receptors (5). We therefore synthesized a peptide derivative of MCT-2 and hMCT-2 with an N-terminal free amino group and evaluated their abilities to induce ␤-HA release from differentiated HL-60 cells. The peptide derivatives with an N-terminal free amino group of MCT-2 and hMCT-2 caused significant ␤-HArelease; however, their activities were ϳ1/10,000 those of MCT-2 and hMCT-2 (data not shown), thus showing the importance of the N-terminal formyl group of these peptides for their activities.
We then investigated the competitive effects of MCT-2 and hMCT-2 on the binding of fMLF to differentiated HL-60 cells, since their N-terminal is formylated as fMLF. MCT-2 and hMCT-2 inhibited [ 3 H]fMLF binding to intact cells in a concentration-dependent manner. However, the inhibition of [ 3 H]fMLF binding by MCT-2 and hMCT-2 was partial even at 100 M. In contrast, nonlabeled fMLF completely inhibited [ 3 H]fMLF binding (Fig. 6A) . Since FPR and FPRL1 are present in differentiated HL-60 cells (32) (33) (34) , the results suggest that the receptor for MCT-2 and hMCT-2, at least in part, may either be FPR or FPRL1.
Chemoattractants such as fMLF, C5a, IL-8, and MCT-1 are known to stimulate neutrophils by activating G i -type G proteins (12, 32, 35) . Therefore, we next investigated the involvement of G i -or G o -type G proteins in stimulating ␤-HA release, chemotaxis, and [Ca 2ϩ ] i increase induced by hMCT-2 in HL-60 cells differentiated into neutrophilic/granulocytic cells utilizing PTX, which induces the ADP-ribosylation of G i -or G o -type G proteins and renders them insensitive to stimulation (35) . As shown in Fig.  6B , ␤-HA release, chemotaxis, and the increase in [Ca 2ϩ ] i stimulated by hMCT-2 and fMLF were completely inhibited by the pretreatment with 50 ng/ml PTX for 16 h. These findings indicate that hMCT-2 exerts its effects via the activation of G i or G o proteins.
Effects of MCT-2 and hMCT-2 on neutrophils
To investigate whether MCT-2 and hMCT-2 are functional peptides even in neutrophils, we examined their effects on ␤-HA release in neutrophils isolated and purified from human peripheral blood of healthy volunteers. As shown in Fig. 7 , MCT-2 and hMCT-2 significantly stimulated ␤-HA secretion even in human neutrophils at a concentration above 1 M in the dose-dependent manner as did fMLF. Additionally, MCT-2 and hMCT-2 as well as the control peptide fMLF at 300 M caused no significant LDH leakage. These results demonstrate that MCT-2 and hMCT-2 are neutrophil-activating peptides.
Discussion
In the present study, we isolated and identified a novel neutrophilactivating peptide, MCT-2, from porcine hearts and demonstrated that its human homolog, hMCT-2, activates not only HL-60 cells differentiated into neutrophilic/granulocytic cells but also human neutrophils purified from peripheral blood. Additionally, G i -or G o -type G proteins are suggested to be involved in the activation of signaling pathways of the differentiated HL-60 cells by hMCT-2. We determined the primary sequence of MCT-2 by MS/MS analysis using FAB-MS and the Edman analysis of fragmented peptides of MCT-2 produced by Arg-C digestion. The presence of unidentified modification(s) was suggested by the MS analyses; however, it appeared unessential for the activities of MCT-2 due to the following reasons: 1) the purified peptide had a similar potency to the chemically synthesized MCT-2 in the HL-60 cells differentiated into neutrophilic/granulocytic cells (stimulation of ␤-HA release, 87.5% of the positive control by the purified peptide at 12 nM (Fig. 3C ) (estimated from the data of the Edman analysis after Arg-C digestion); 86.1% of the positive control by the synthesized MCT-2 at 10 nM ( Fig. 5B)) ; and 2) the derivative peptides of MCT-2 and hMCT-2 in which their C terminus was extended or truncated showed similar activities to MCT-2 or hMCT-2; nevertheless, the C-terminal modification of MCT-2 most likely occurred.
Neutrophils are thought to recognize N-terminal formylated peptides and proteins to monitor bacterial infection because bacterial proteins are biosynthesized as formylated forms at their N termini (3, 5) . Similar to bacterial proteins but not nuclear DNAencoded mitochondrial proteins (which are nonformylated at their N termini), mammalian proteins encoded in mitochondrial DNA are produced as N-terminal formylated forms, supporting the notion that they become chemoattractants of neutrophils. In fact, Carp reported that disrupted mitochondria induced chemotaxis in neutrophils, and N-terminal formylated proteins such as cytochrome oxidase and ATPase may cause this effect (7). Additionally, N-terminal formylated forms, that is, not only N-terminal formylated mitochondrial proteins but also synthetic peptides derived from NADH dehydrogenase subunit I, caused neutrophil migration (8) . On the basis of these results, several groups have hypothesized that mitochondrial N-terminal formylated proteins are released from damaged tissues to initiate inflammatory reactions (3, 7, 8) . However, most of the N-terminal formylated proteins encoded in mitochondrial DNA are membrane proteins, and therefore it is difficult to disperse these proteins as neutrophil-migrating factors without proteolytic cleavages. In this regard, the presence of any of N-terminal formylated peptides derived from mammalian tissues has not yet been demonstrated. The present study is the first to show the presence of an N-terminal formylated peptide endogenously. We are currently investigating the presence of hMCT-2, a human homolog of MCT-2, in human mitochondria utilizing the recently developed mass spectrometry technique, and have found the presence of various peptides (H. Mukai, unpublished observation). Despite our ongoing studies, we have not yet been able to directly demonstrate the presence of hMCT-2 in humans; however, MCT-2 homologs in various mammals, including cows, rats, and mice as well as humans, are thought to exist because the N-terminal sequences of cytochrome b are preserved mostly throughout these species.
What are the possible physiological and/or pathophysiological roles of MCT-2? It is well known that neutrophils immediately transmigrate from the bloodstream to inflammatory sites when tissue injury occurs. We have not observed any effects of MCT-2 or hMCT-2 on monocytes, lymphocytes, or mast cells at present (H. Mukai, unpublished data). Additionally, MCT-2 and hMCT-2 induced ␤-HA release, chemotaxis, and [Ca 2ϩ ] i increase in HL-60 cells differentiated into neutrophilic/granulocytic cells but not in undifferentiated cells (Figs. 5 and 6 ). These findings suggest that the effects of MCT-2 and hMCT-2 may be specific to neutrophils. MCT-2 and hMCT-2 presumably exist in mitochondria and are expected to be one of the factors inducing immediate migration of neutrophils specifically by forming a concentration gradient in injury sites. Namely, MCT-2 and hMCT-2 induced neutrophilic migration at a lower concentration than that causing ␤-HA release. The migration activities induced by MCT-2 and hMCT-2 were completely desensitized at the concentrations that induced ␤-HA release; that is, the concentrations inducing chemotaxis were distinguished from those inducing ␤-HA release (Fig. 5B) . These results suggest the following hypothesis: MCT-2 and hMCT-2 released from tissue injury sites form their concentration gradient in inflammatory sites after tissue injury, and this concentration gradient of MCT-2 and hMCT induces neutrophilic transmigration from the bloodstream to the inflammatory sites. During migration, neutrophils may not be activated; however, they are activated when they come close to the injury sites to scavenge toxic cell debris.
In the present study, the signaling mechanisms stimulated by hMCT-2 were investigated, and G i -or G o -type G proteins were indicated to be involved in the signaling pathways as in the case of known neutrophil-activating factors such as MCT-1 and fMLF (12, 35) . The receptor molecule of MCT-2 and hMCT-2 may be one of the formyl peptide receptors, since [ 3 H]fMLF binding was inhibited by MCT-2 or hMCT-2. However, the binding inhibition was partial, and therefore further investigation is required for the determination of the receptor molecule(s) of MCT-2 or hMCT-2.
We have also purified several neutrophil-activating peptides derived from nucleic DNA-encoded mitochondrial proteins, whose N termini are not formylated, including MCT-1, a C-terminal tricosapeptide of mitochondrial cytochrome c oxidase subunit VIII; we have recently designated such bioactive peptides hidden in protein FIGURE 7. Effects of MCT-2, its human homolog hMCT-2, and fMLF on ␤-HA release from neutrophils isolated and purified from human peripheral blood of five independent healthy volunteers. The ability of each peptide to cause ␤-HA release was expressed as a percentage of the total enzyme activity, which was the enzyme activity released after disruption of the cells with 0.05% Triton X-100 (%/total content). Data are expressed as means Ϯ SE of five independent experiments. ‫,ءء‬ p Ͻ 0.01, values significantly different from the values without stimulation by peptides.
structures as "cryptides" (12, 36 -38) . Our findings also suggest that the functions of neutrophils at inflammatory sites are regulated by diverse mitochondria-derived peptides, including not only Nterminal formylated peptides but also other classes of peptides. At inflammatory sites, various substances including CXC chemokines such as IL-8, complement factors such as C5a, and small chemicals such as a platelet-activating factor and leukotriene B 4 induce neutrophilic migration (1) (2) (3) (4) . Additionally, protein fragments originating from elastin and aminoacyl-tRNA synthetase show neutrophil-migrating activity (39, 40) . Mitochondria-derived substances may synergize with these factors to heal inflammation, and the identification of various neutrophil-activating substances (including peptidergic factors) present at tissue injury sites is critical for the comprehensive understanding of neutrophil functions. However, the identification of such peptidergic factors is a time-and labor-intensive process; that is, most bioactive peptides become mature after proteolytic cleavage from inactive precursor proteins, and thus recently developed molecular biological methodologies cannot be applied for their identification. Therefore, bioactive peptides need to be purified from various tissues, and, in fact, it has taken us 6 years to identify MCT-2. Currently, we are identifying neutrophil-activating peptides by predicting functional peptides in light of their physicochemical properties and the presence of proteolytic cleavage sites by utilizing information accumulated in our purification and identification studies of neutrophil-activating peptides including the present peptide (H. Mukai, manuscript in preparation).
